Goodrx Holdings Inc
NASDAQ:GDRX
Goodrx Holdings Inc
No
Economic Moat
Goodrx Holdings Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Goodrx Holdings Inc
Competitive Advantages
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$178.56 |
+0.8%
|
$4.3T | Wide |
|
|
|
Apple Inc
AAPL
|
$248.8416 |
+2.1%
|
$3.7T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$307.13 |
-0.2%
|
$3.7T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$389.02 |
+1%
|
$2.9T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$208.76 |
+1.6%
|
$2.2T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 850 |
+2.4%
|
$1.5T | Wide |
|
|
|
Meta Platforms Inc
META
|
$606.7 |
+0.1%
|
$1.5T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$319.84 |
-1.8%
|
$1.5T | Wide |
|
|
|
Walmart Inc
WMT
|
$121.09 |
+0.6%
|
$965.1B | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$917.5 |
-1.3%
|
$867.4B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
Royal Bank of Canada
RY
|
CA$220.25 |
-0.3%
|
$225.1B | Wide |
|
|
|
Toronto-Dominion Bank
TD
|
CA$128.64 |
-0.6%
|
$159.3B | Wide |
|
|
|
Canadian Pacific Railway Ltd
CP
|
CA$107.84 |
+1.4%
|
$70.7B | Wide |
|
|
|
Canadian National Railway Co
CNR
|
CA$136.12 |
+0.7%
|
$61.3B | Wide |
|
|
|
Corteva Inc
CTVA
|
$78.07 |
+1.5%
|
$52.8B | Wide |
|
|
|
W W Grainger Inc
GWW
|
$1 043.05 |
+0.6%
|
$49.6B | Wide |
|
|
|
AMETEK Inc
AME
|
$211.5 |
+1.8%
|
$48.7B | Wide |
|
|
|
Yum! Brands Inc
YUM
|
$156.25 |
-0.5%
|
$43.4B | Wide |
|
|
|
Waste Connections Inc
WCN
|
CA$226.3 |
+1.6%
|
$42.3B | Wide |
|
|
|
Thomson Reuters Corp
TRI
|
CA$128.2 |
+10.4%
|
$41.6B | Wide |
Goodrx Holdings Inc
Glance View
GoodRx Holdings Inc., established at the intersection of healthcare and technology, has carved a niche in the American pharmaceutical industry by addressing one of its most notorious challenges: the high cost of prescription medications. Originally founded in 2011, GoodRx aims to ease the financial burden of medication costs for consumers by providing a platform that aggregates drug pricing information from pharmacies across the United States. By doing so, it empowers users to compare prices, identify potential savings, and subsequently make informed decisions about their medication purchases. At its core, GoodRx operates as a digital intermediary; its app and website seamlessly connect consumers with discounted prescription offers through partnerships with pharmacy benefit managers (PBMs) and retail pharmacies. The company's revenue model is primarily built on a commission and advertising framework. When users select a coupon from GoodRx and purchase at a pharmacy, the company receives a fee from its pharmacy partners or PBMs. Additionally, GoodRx leverages its vast user base, which is largely driven by organic traffic resulting from the essential nature of its service, to generate advertising revenues from pharmaceutical companies and other health-related entities eager to reach consumers actively seeking medication solutions. By continually expanding its services, such as telehealth offerings and a subscription model called GoodRx Gold, the company seeks to deepen its integration into the consumer healthcare experience while maintaining its core mission of providing accessible and affordable medication options.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat